I would like to share with you some exciting news we received during the special celebration that took place this week. On Tuesday, we held our annual Hadassah Research Day.
Hadassah’s Cell Cure Neurosciences Ltd. has entered into an exclusive license option agreement with Teva Pharmaceutical Industries to develop and commercialize OpRegen™, Hadassah’s stem-cell product for the treatment of Age-related Macular Degeneration (AMD). Cell Cure is a subsidiary of Hadasit Bio Holdings, the Hadassah Medical Center’s technology transfer company, and BioTime, Inc.
Israel’s Ministry of Health has given approval for the Hadassah Medical Center and BrainStorm Cell Therapeutics Inc., the leading developer of stem cell technologies, to partner for a clinical trial of BrainStorm’s stem cell treatment for Amyotrophic Lateral Sclerosis (ALS) at Hadassah.
When the large brain aneurysm of a 35-year-old patient doubled in size in ten days, Endovascular Neurosurgeon and Interventional Neuroradiologist Prof. José Cohen and his colleagues in the Department of Neurosurgery at Hadassah Hospital-Ein Kerem pioneered a new technique to save his life.
When their three-year-old child was killed in a tragic accident, the Palestinian parents decided to donate his liver and lungs, giving three people a new chance at life.
The patients at Hadassah Hospital welcomed the Jewish New Year with the traditional apple dipped in honey, signifying hopes for a sweet year to come. Those who were well enough celebrated together at a festive communal meal, for which Hadassah purchased nearly 400 pounds of apples and 44 pounds of honey.
Click the mouse to bring a three-dimensional human figure onto the screen. Click again, and the figure rotates. Another click, and the skin melts off to show the muscles and nerves.
At the European Cystic Fibrosis Society (ECFS) Conference in Spain this past June, Prof. Eitan Kerem, head of Pediatrics at Hadassah Hospital-Ein Kerem and its Cystic Fibrosis Center, ended his presentation about the CF Center that Hadassah made possible in Gaza, with this slide. “There was an audible gasp of shock from the entire audience,” Prof. Kerem recalls. He then showed the same photograph from a wider angle, which revealed that the red color was the result of deeply red autumn leaves reflecting on the water. Prof. Kerem told his audience, “Not everything you see is what it seems to be.” The applause was almost deafening, he relates. Following his presentation, Prof. Kerem was approached by medical professionals from Arab countries who expressed interest in coming to Hadassah to specialize in cystic fibrosis. (See June 2010 eBulletin to read about the CF Center in Gaza.)
Oramed Pharmaceuticals Inc., a Jerusalem-based company partly owned by Hadassah Medical Center, has announced success of its clinical trial which tested the effectiveness of its oral insulin capsule on patients suffering from uncontrolled Type 1 diabetes.
Against almost all odds, 28-year-old Arin Nasser, who was born with thalassemia (a potentially fatal genetic disease), gave birth to a healthy baby boy at the Hadassah Medical Center, thanks to a unique procedure of implanting her previously frozen ovarian tissue.